Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | LIPE | Q05469 | 8/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606435 | 0.88 | EGFR (0.37) | EGFRLIPEDGAT1UCHL1TDO2 | |
| SCHEMBL26658292 | 0.88 | EGFR (0.37) | EGFRLIPEDGAT1UCHL1TDO2 | |
| SCHEMBL1484903 | 0.83 | NNMT (0.41) | EGFRLIPEDGAT1UCHL1NNMT | |
| SCHEMBL29421574 | 0.83 | NNMT (0.41) | EGFRLIPEDGAT1UCHL1NNMT | |
| SCHEMBL31042949 | 0.81 | DGAT1 (0.34) | EGFRLIPEDGAT1UCHL1TDO2 | |
| SCHEMBL25428075 | 0.81 | LIPE (0.37) | EGFRLIPEDGAT1 | |
| SCHEMBL18225077 | 0.80 | EGFR (0.33) | EGFRLIPE | |
| SCHEMBL20519939 | 0.79 | NNMT (0.37) | EGFRLIPEDGAT1UCHL1NNMT | |
| SCHEMBL29652860 | 0.79 | NNMT (0.37) | EGFRLIPEDGAT1UCHL1NNMT | |
| SCHEMBL20519408 | 0.79 | UCHL1 (0.40) | EGFRLIPEDGAT1UCHL1NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4043466-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4404932-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | Oric Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20210230168-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20210101904-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-04-08 | — | — | US | disclosed |
| US-20210101904-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-04-08 | — | — | US | disclosed |
| US-20210032252-A1 | PRC2 Inhibitors | Mirati Therapeutics, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-20210032252-A1 | PRC2 Inhibitors | Mirati Therapeutics, Inc. | 2021-02-04 | — | — | US | disclosed |
| WO-2020247475-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247475-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2019152419-A1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS, INC (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | EGFR 1827/4885LIPE 4879/4885DGAT1 3128/4885 |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | BMI1, EZH2, SUZ12 | EGFR 2159/4885LIPE 4584/4885DGAT1 2474/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | EGFR 1035/4885LIPE 4748/4885DGAT1 2584/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | EGFR 2159/4885LIPE 4584/4885DGAT1 2474/4885 |
| US-20210101904-A1 | PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | EGFR 1137/4885LIPE 4076/4885DGAT1 1231/4885 |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | EZH2, BMI1, EZH1 | EGFR 4410/4885LIPE 4694/4885DGAT1 1908/4885 |
| US-20210032252-A1 | PRC2 Inhibitors | EZH2, BMI1, SUZ12 | EGFR 1137/4885LIPE 4076/4885DGAT1 1231/4885 |
| US-20210230168-A1 | PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | EGFR 1137/4885LIPE 4076/4885DGAT1 1231/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | EGFR 527/4885LIPE 2473/4885DGAT1 2524/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | EGFR 1501/4885LIPE 4230/4885DGAT1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.